This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Biotech Stock Mailbag: Peregrine, Arena, Dendreon, NPS Pharma

Stocks in this article: ARNA PPHM VVUS NPSP DNDN

BOSTON ( TheStreet) -- The Biotech Stock Mailbag is back for its seventh year!

Seth T. writes: "I checked your site but couldn't find anything on Peregrine Pharmaceuticals (PPHM - Get Report) and the update on the bavituximab data. How do you judge the company's conclusions in regards to this matter? I'm hesitant to give them the benefit of the doubt after what happened but perhaps bavituximab has a future role to play in lung cancer. I appreciate your thoughts."

I didn't get a chance to write about Peregrine's bavituximab update because I was busy covering the JPMorgan Healthcare Conference. I did tweet my thoughts (snarkily):



Peregrine's attempt to resurrect the bavituximab second-line lung cancer data is a colossal waste of time. The data are corrupted and nothing the company says or does will change that fact. Peregrine claims drug vial coding discrepancies were isolated to placebo and the 1 mg bavituximab dose, leaving the 3 mg bavituximab vials pristine.

Peregrine believes a "conservative" approach to resurrecting the lung cancer study results will be to combine the placebo and 1 mg bavituximab doses into a single control arm, which can be compared against the 3 mg bavituximab dose.

Nonsense. For starters, the evidence by which Peregrine concludes only the placebo and 1 mg bavituximab vials were corrupted is ridiculously flimsy. The company has only managed to obtain full pharmacokinetic (drug blood level) data on 18 of 120 patients in the study, according to an investor who met with Peregrine executives last week.

Pharmacokinetic data is the only way to determine which patients truly received drug or placebo. Peregrine also has antibody data on patients but this information can't distinguish between the 1 mg and 3 mg bavituximab dose, so it's not helpful.

Even if we buy into Peregrine's spin, the consolidation of the placebo and 1 mg bavituximab dose into a single control arm is absurd. Peregrine doesn't have the right to write its own rules governing data analysis. Again, if you believe the 3 mg bavituximab data are clean (which I don't), then the best Peregrine can do is throw out the placebo and 1 mg bavituximab data entirely, turning the phase II study into a single-arm, uncontrolled trial from which no conclusion on a survival benefit can be made.

"With the results of this review in hand, we are now in the process of updating potential partners and moving the program forward," said Peregrine CEO Steven King, in the company's Jan. 7 statement.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,678.70 +6.10 0.03%
S&P 500 2,057.09 +5.27 0.26%
NASDAQ 4,771.7630 +13.8840 0.29%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs